http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150121869-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69f43505d1b3ec31c224b32b5d1ec4e2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a80f21feb68e70a6b51c8558339599 |
| publicationDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150121869-A |
| titleOfInvention | Method of Selecting an anti-cancer drug for loading on an anti-cancer patch |
| abstract | The present invention relates to genetic markers for diagnosis of surgical prognosis and selection of anticancer agents. More particularly, the present invention relates to a genetic marker for diagnosing prognosis of a pancreatic cancer patient through genetic mutation, and a K-ras gene for selecting an anticancer agent suitable for each genetic mutation Or DPC4 gene markers. Based on the mutation of K-ras gene and the expression level of DPC4 according to the present invention, the method of diagnosing post-operative prognosis after pancreatic cancer surgery is based on gene mutation and survival analysis of large-scale Korean pancreatic cancer patients, Of patients with pancreatic cancer who are at high risk for pancreatic cancer surgery and considering the mechanism of action against these genes, it is useful information for determining the proper selection, dosage and concentration of anticancer drugs after pancreatic cancer surgery. . |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200079029-A |
| priorityDate | 2014-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.